NO20020759D0 - N<o>6</o> heterocykliske substituerte adenosinderivater - Google Patents

N<o>6</o> heterocykliske substituerte adenosinderivater

Info

Publication number: NO20020759D0
Authority: NO; Norway
Prior art keywords: heterocyclic substituted; adenosine derivatives; substituted adenosine; sub; substituted
Prior art date: 1996-08-27

Application number

NO20020759A

Other languages

English (en)

Other versions

NO20020759L (no

Inventor

Robert T Lum

Jurg R Pfister

Steven R Schow

Michael M Wick

Marek G Nelson

George F Schreiner

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

2002-02-15

Publication date

2002-02-15

1999-02-19 Publication of NO20020759L publication Critical patent/NO20020759L/no

2002-02-15 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2002-02-15 Priority to NO20020759A priority Critical patent/NO20020759D0/no

2002-02-15 Publication of NO20020759D0 publication Critical patent/NO20020759D0/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20020759A 1996-08-27 2002-02-15 N<o>6</o> heterocykliske substituerte adenosinderivater NO20020759D0 (no)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NO20020759A NO20020759D0 (no)	1996-08-27	2002-02-15	N<o>6</o> heterocykliske substituerte adenosinderivater

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US08702234 US5789416B1 (en)	1996-08-27	1996-08-27	N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en)	1996-08-27	1997-08-20	N6 heterocyclic substituted adenosine derivatives
NO19990787A NO312679B1 (no)	1996-08-27	1999-02-19	N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020759A NO20020759D0 (no)	1996-08-27	2002-02-15	N<o>6</o> heterocykliske substituerte adenosinderivater

Publications (2)

Publication Number	Publication Date
NO20020759L NO20020759L (no)	1999-02-19
NO20020759D0 true NO20020759D0 (no)	2002-02-15

Family

ID=24820367

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19990787A NO312679B1 (no)	1996-08-27	1999-02-19	N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020758A NO322459B1 (no)	1996-08-27	2002-02-15	N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.
NO20020759A NO20020759D0 (no)	1996-08-27	2002-02-15	N<o>6</o> heterocykliske substituerte adenosinderivater

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO19990787A NO312679B1 (no)	1996-08-27	1999-02-19	N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020758A NO322459B1 (no)	1996-08-27	2002-02-15	N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Country Status (24)

Country	Link
US (1)	US5789416B1 (no)
EP (3)	EP1081155A3 (no)
JP (1)	JP3157842B2 (no)
KR (1)	KR100331775B1 (no)
CN (1)	CN100363377C (no)
AT (2)	ATE234323T1 (no)
AU (1)	AU726597B2 (no)
BR (1)	BR9711444A (no)
CA (1)	CA2264155C (no)
CZ (1)	CZ296855B6 (no)
DE (2)	DE69705312T2 (no)
DK (2)	DK0992510T3 (no)
ES (2)	ES2157593T3 (no)
GE (1)	GEP20012419B (no)
GR (1)	GR3036332T3 (no)
HU (1)	HU226057B1 (no)
IL (2)	IL128652A0 (no)
NO (3)	NO312679B1 (no)
NZ (3)	NZ334095A (no)
PL (1)	PL187635B1 (no)
PT (1)	PT920438E (no)
TR (2)	TR200202287T2 (no)
UA (1)	UA62936C2 (no)
WO (1)	WO1998008855A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6790839B2 (en)	1999-01-07	2004-09-14	Can-Fite Biopharma Ltd.	Pharmaceutical administration of adenosine agonists
IL127947A0 (en)	1999-01-07	1999-11-30	Can Fite Technologies Ltd	Pharmaceutical use of adenosine agonists
US6576619B2 (en) *	1999-05-24	2003-06-10	Cv Therapeutics, Inc.	Orally active A1 adenosine receptor agonists
CA2373279A1 (en) *	1999-05-25	2000-12-14	The Penn State Research Foundation	Dna methyltransferase inhibitors
EP1420021A1 (en) *	1999-05-25	2004-05-19	The Penn State Research Foundation	DNA Methyltransferase inhibitors
US6180615B1 (en) *	1999-06-22	2001-01-30	Cv Therapeutics, Inc.	Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en)	1999-11-23	2004-08-31	Aderis Pharmaceuticals, Inc.	Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6605597B1 (en) *	1999-12-03	2003-08-12	Cv Therapeutics, Inc.	Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) *	1999-12-03	2001-09-25	Cv Therapeutics, Inc.	N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en)	1999-12-03	2001-07-10	Cv Therapeutics, Inc.	N6 heterocyclic 5′ modified adenosine derivatives
WO2001040799A2 (en) *	1999-12-03	2001-06-07	Cv Therapeutics, Inc.	Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
PL205874B1 (pl) *	2000-09-08	2010-06-30	Cv Therapeutics	Zastosowanie agonisty receptora adenozyny A₁ do wytwarzania leku do leczenia arytmii serca
GB0100623D0 (en) *	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds IV
EP1241176A1 (en) *	2001-03-16	2002-09-18	Pfizer Products Inc.	Purine derivatives for the treatment of ischemia
US20050227933A1 (en) *	2001-11-29	2005-10-13	Benkovic Stephen J	Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
CA2473238A1 (en) *	2002-01-10	2003-07-24	The Penn State Research Foundation	Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids
EP2412716A1 (en)	2002-02-19	2012-02-01	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
AU2003235466C1 (en) *	2002-04-18	2008-03-20	Gilead Palo Alto, Inc.	Method for treating arrhythmias
ATE333455T1 (de)	2002-05-17	2006-08-15	Neurogen Corp	Substituierte, ringkondensierte imidazolderivate: gabaa-rezeptorliganden
US7163928B2 (en) *	2003-02-03	2007-01-16	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
EP1615931A1 (en)	2003-04-09	2006-01-18	Biogen Idec MA Inc.	Triazolopyrazines and methods of making and using the same
US7285550B2 (en)	2003-04-09	2007-10-23	Biogen Idec Ma Inc.	Triazolotriazines and pyrazolotriazines and methods of making and using the same
EP1633756B1 (en)	2003-04-09	2008-12-24	Biogen Idec MA Inc.	A2a adenosine receptor antagonists
US20050009776A1 (en) *	2003-04-24	2005-01-13	Aderis Pharmaceuticals, Inc.	Method of treating atrial fibrillation or atrial flutter
WO2005025545A2 (en) *	2003-09-17	2005-03-24	Aderis Pharmaceuticals, Inc.	Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) *	2004-04-21	2005-04-19	Eastman Chemical Company	Preparation of tetrahydro-3-furoic acid
CN103087133B (zh) *	2004-05-26	2016-09-14	伊诺泰克制药公司	嘌呤衍生物作为腺苷a1受体激动剂及其用法
BRPI0515506A (pt) *	2004-09-20	2008-07-29	Inotek Pharmaceuticals Corp	derivados de purina e métodos de uso dos mesmos
CN100451010C (zh) *	2004-12-21	2009-01-14	厦门大学	一种合成(r)-3-氨基四氢呋喃的方法
WO2006125190A1 (en) *	2005-05-19	2006-11-23	Cv Therapeutics, Inc.	A1 adenosine receptor agonists
EP2218442A1 (en)	2005-11-09	2010-08-18	CombinatoRx, Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
CN100344768C (zh) *	2005-11-24	2007-10-24	东华大学	一种3－(s)－氨基四氢呋喃的酶法合成方法
NZ568392A (en) *	2005-11-30	2011-07-29	Inotek Pharmaceuticals Corp	Purine derivatives and methods of use thereof
AU2009213147A1 (en)	2008-02-11	2009-08-20	Rxi Pharmaceuticals Corp.	Modified RNAi polynucleotides and uses thereof
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
CN102405286A (zh)	2008-09-22	2012-04-04	阿克赛医药公司	减小大小的自递送RNAi化合物
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2523669B1 (en)	2010-01-11	2016-12-07	Inotek Pharmaceuticals Corporation	Combination, kit and method of reducing intraocular pressure
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
KR20180044433A (ko)	2010-03-24	2018-05-02	알엑스아이 파마슈티칼스 코포레이션	진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
RU2615143C2 (ru)	2010-03-24	2017-04-04	Адвирна	Самодоставляющие PHKi соединения уменьшенного размера
JP2013523739A (ja)	2010-03-26	2013-06-17	イノテックファーマシューティカルズコーポレイション	Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
DE102011005232A1 (de)	2011-03-08	2012-09-13	AristoCon GmbH & Co. KG	Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
NZ627778A (en)	2012-01-26	2017-01-27	Inotek Pharmaceuticals Corp	Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
BR112015021870A2 (pt)	2013-03-15	2017-07-18	Inotek Pharmaceuticals Corp	formulações oftálmicas
CN113151180A (zh)	2013-12-02	2021-07-23	菲奥医药公司	癌症的免疫治疗
CN105960265A (zh)	2013-12-04	2016-09-21	阿克赛医药公司	利用经化学修饰的寡核苷酸处理伤口愈合的方法
WO2015168108A2 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic targeting mdm2 or mycn
US20170051290A1 (en)	2014-05-01	2017-02-23	Rxi Pharmaceuticals Corporation	Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR102689262B1 (ko)	2014-09-05	2024-07-30	피오 파마슈티칼스 코프.	Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CN108135923B (zh)	2015-07-06	2021-03-02	菲奥医药公司	靶向超氧化物歧化酶1（sod1）的核酸分子
WO2017007825A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3365446A4 (en)	2015-10-19	2019-06-26	Phio Pharmaceuticals Corp.	SMALL SELF-LEANING NUCLEIC ACID COMPOUNDS TURNED AGAINST LONG NON-CODING RNA
CN105218490B (zh) *	2015-11-10	2017-05-03	山东川成医药股份有限公司	一种（r）‑3‑氨基四氢呋喃的制备方法
EP3612152A4 (en)	2017-04-19	2021-02-17	Phio Pharmaceuticals Corp.	TOPICAL ADMINISTRATION OF NUCLEIC ACID COMPOUNDS
CA3160657A1 (en)	2019-11-08	2021-05-14	Phio Pharmaceuticals Corp.	Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
US20230089478A1 (en)	2019-12-31	2023-03-23	Phio Pharmaceuticals Corp.	Chemically modified oligonucleotides with improved systemic delivery
WO2023015264A1 (en)	2021-08-04	2023-02-09	Phio Pharmaceuticals Corp.	Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
EP4381070A2 (en)	2021-08-04	2024-06-12	Phio Pharmaceuticals Corp.	Chemically modified oligonucleotides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2460929A1 (de) *	1974-12-21	1976-06-24	Boehringer Sohn Ingelheim	Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) *	1980-10-14	1982-12-21	University Of Virginia Alumni Patents Foundation	Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) *	1981-04-15	1982-10-22	Fujisawa Pharmaceut Co Ltd	Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) *	1981-09-26	1983-04-07	Hoechst Ag, 6230 Frankfurt	"arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
AU577743B2 (en) *	1984-10-26	1988-09-29	Warner-Lambert Company	N6-benzopyrano and benzothiopyrano adenosines
AU8274187A (en) *	1986-10-31	1988-05-25	Warner-Lambert Company	Heteroaromatic derivatives of adenosine
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) *	1987-04-24	1996-10-15	Discovery Therapeutics, Inc.	N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) *	1988-06-30	1990-12-25	The University Of Virginia	Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) *	1988-08-25	1990-02-25	Prendergast Patrick T	Viral treatment system
DE3843117A1 (de) *	1988-12-22	1990-06-28	Boehringer Ingelheim Kg	Neue xanthinderivate mit adenosin-antagonistischer wirkung
EP0457773A4 (en) *	1989-01-31	1993-03-10	Whitby Research Incorporated	N?6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5155098A (en) *	1989-06-09	1992-10-13	Hoechst-Roussel Pharmaceuticals Inc.	N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5017578A (en) *	1989-06-09	1991-05-21	Hoechst-Roussel Pharmaceuticals Inc.	N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) *	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
DE4019892A1 (de) *	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
US5432164A (en) *	1991-10-24	1995-07-11	Novo Nordisk A/S	C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) *	1992-02-21	2005-11-24	Glüsenkamp, Karl-Heinz, Dr.	Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) *	1992-09-22	1994-02-22	Cell Therapeutics, Inc.	Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) *	1993-01-26	1994-08-04	Kyowa Hakko Kogyo Co., Ltd.	Medicament contre l'elimination irreguliere des matieres fecales
US5446046A (en) *	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) *	1993-10-28	1998-04-07	University Of Florida Research Foundation, Inc.	N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
EP0704215A3 (en) *	1994-06-02	1998-04-01	Takeda Chemical Industries, Ltd.	Inhibitor of vascular permeability enhancer

1996
- 1996-08-27 US US08702234 patent/US5789416B1/en not_active Expired - Lifetime
1997
- 1997-08-20 TR TR2002/02287T patent/TR200202287T2/xx unknown
- 1997-08-20 IL IL12865297A patent/IL128652A0/xx active IP Right Grant
- 1997-08-20 CA CA002264155A patent/CA2264155C/en not_active Expired - Fee Related
- 1997-08-20 AT AT99119389T patent/ATE234323T1/de active
- 1997-08-20 WO PCT/US1997/014724 patent/WO1998008855A2/en not_active Ceased
- 1997-08-20 GE GEAP19974728A patent/GEP20012419B/en unknown
- 1997-08-20 CN CNB971991790A patent/CN100363377C/zh not_active Expired - Fee Related
- 1997-08-20 EP EP00123879A patent/EP1081155A3/en not_active Withdrawn
- 1997-08-20 EP EP97938502A patent/EP0920438B1/en not_active Expired - Lifetime
- 1997-08-20 CZ CZ0061499A patent/CZ296855B6/cs not_active IP Right Cessation
- 1997-08-20 EP EP99119389A patent/EP0992510B1/en not_active Expired - Lifetime
- 1997-08-20 NZ NZ334095A patent/NZ334095A/xx not_active IP Right Cessation
- 1997-08-20 BR BR9711444-8A patent/BR9711444A/pt active Search and Examination
- 1997-08-20 HU HU0001640A patent/HU226057B1/hu not_active IP Right Cessation
- 1997-08-20 DK DK99119389T patent/DK0992510T3/da active
- 1997-08-20 AU AU40809/97A patent/AU726597B2/en not_active Ceased
- 1997-08-20 ES ES97938502T patent/ES2157593T3/es not_active Expired - Lifetime
- 1997-08-20 DE DE69705312T patent/DE69705312T2/de not_active Expired - Lifetime
- 1997-08-20 TR TR1999/00377T patent/TR199900377T2/xx unknown
- 1997-08-20 NZ NZ505428A patent/NZ505428A/en unknown
- 1997-08-20 AT AT97938502T patent/ATE202361T1/de active
- 1997-08-20 ES ES99119389T patent/ES2189330T3/es not_active Expired - Lifetime
- 1997-08-20 DK DK97938502T patent/DK0920438T3/da active
- 1997-08-20 PT PT97938502T patent/PT920438E/pt unknown
- 1997-08-20 JP JP51173698A patent/JP3157842B2/ja not_active Expired - Fee Related
- 1997-08-20 KR KR1019997001563A patent/KR100331775B1/ko not_active Expired - Fee Related
- 1997-08-20 PL PL97331853A patent/PL187635B1/pl not_active IP Right Cessation
- 1997-08-20 DE DE69719816T patent/DE69719816T2/de not_active Expired - Lifetime
- 1997-08-20 UA UA99021148A patent/UA62936C2/uk unknown
1999
- 1999-02-19 NO NO19990787A patent/NO312679B1/no not_active IP Right Cessation
- 1999-02-22 IL IL128652A patent/IL128652A/en not_active IP Right Cessation
2001
- 2001-06-08 NZ NZ512242A patent/NZ512242A/xx not_active IP Right Cessation
- 2001-08-06 GR GR20010401184T patent/GR3036332T3/el unknown
2002
- 2002-02-15 NO NO20020758A patent/NO322459B1/no not_active IP Right Cessation
- 2002-02-15 NO NO20020759A patent/NO20020759D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0992510A1 (en)	2000-04-12
CZ61499A3 (cs)	1999-10-13
KR20000035867A (ko)	2000-06-26
US5789416B1 (en)	1999-10-05
NZ334095A (en)	2000-10-27
NZ512242A (en)	2004-01-30
IL128652A (en)	2008-06-05
NO322459B1 (no)	2006-10-09
GEP20012419B (en)	2001-04-25
NO312679B1 (no)	2002-06-17
CA2264155C (en)	2003-11-18
IL128652A0 (en)	2000-01-31
HUP0001640A2 (hu)	2001-05-28
NO990787D0 (no)	1999-02-19
DK0920438T3 (da)	2001-09-10
DE69719816T2 (de)	2003-12-18
GR3036332T3 (en)	2001-11-30
PL187635B1 (pl)	2004-08-31
TR199900377T2 (xx)	1999-05-21
BR9711444A (pt)	2000-01-18
CA2264155A1 (en)	1998-03-05
CN100363377C (zh)	2008-01-23
AU4080997A (en)	1998-03-19
DE69705312D1 (de)	2001-07-26
EP1081155A3 (en)	2003-05-02
UA62936C2 (en)	2004-01-15
PT920438E (pt)	2001-10-30
EP0920438A2 (en)	1999-06-09
EP1081155A2 (en)	2001-03-07
KR100331775B1 (ko)	2002-04-09
ES2157593T3 (es)	2001-08-16
ATE202361T1 (de)	2001-07-15
ES2189330T3 (es)	2003-07-01
HK1020967A1 (en)	2000-05-26
JP2000501426A (ja)	2000-02-08
NO20020758L (no)	1999-02-19
JP3157842B2 (ja)	2001-04-16
US5789416A (en)	1998-08-04
HU226057B1 (en)	2008-04-28
EP0992510B1 (en)	2003-03-12
EP0920438B1 (en)	2001-06-20
ATE234323T1 (de)	2003-03-15
DK0992510T3 (da)	2003-07-07
NO20020758D0 (no)	2002-02-15
NO990787L (no)	1999-02-19
HUP0001640A3 (en)	2002-04-29
DE69719816D1 (de)	2003-04-17
DE69705312T2 (de)	2001-10-11
NO20020759L (no)	1999-02-19
NZ505428A (en)	2005-03-24
WO1998008855A2 (en)	1998-03-05
AU726597B2 (en)	2000-11-16
TR200202287T2 (tr)	2003-01-21
PL331853A1 (en)	1999-08-16
CN1234803A (zh)	1999-11-10
CZ296855B6 (cs)	2006-07-12
WO1998008855A3 (en)	1998-09-03

Publication	Publication Date	Title
NO20020759L (no)	1999-02-19	N<o>6</o> heterocykliske substituerte adenosinderivater
BR9711262A (pt)	1999-08-17	Derivados 6,6 substituido hetero biciclicos
ATE340176T1 (de)	2006-10-15	Substituierte 6,5-heterobicyclische-derivate
FI954979A7 (fi)	1995-10-18	Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
LU91758I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DK0920429T3 (da)	2003-05-12	Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
DE59501802D1 (de)	1998-05-14	Substituierte 1H-3-Aryl-pyrrolidin-2,4-dion-Derivate
FI914163L (fi)	1992-03-26	Heterocykliska derivat.
IS5089A (is)	1999-06-22	2 - (Púrín - 9 - ýl) tetrahýdrófúran - 3,4 - díólafleiður
NL300203I2 (nl)	2005-11-01	Antiviraal werkzame heterocyclische azahexaan-derivaten.
DK1000048T3 (da)	2003-03-03	Substituerede 1,2,3,4-tetrahydronapthalenderivater
ATE231847T1 (de)	2003-02-15	Substituierte 1,2,3,4- tetrahydronaphthalinderivate
PT843679E (pt)	2002-04-29	Derivados da1-(piperidinil 1,2-disubstituido)-(4-imidazole fundido)-piperidina
TR199802520A3 (tr)	1999-06-21	1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
ATE246199T1 (de)	2003-08-15	3-descladinose-2,3-anhydroerythromycin-derivate
FR11C0047I2 (fr)	2013-01-11	Acides 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-(4.3.0)-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinocarboxyliques eventuellement substitues et leurs derives
ATE214063T1 (de)	2002-03-15	Heterocyclische substituierte pyrrolidinamid- derivate
BR9609310A (pt)	1999-07-06	Derivados de 1,3-OXA(TIA)ZINA
TR199700219A3 (tr)	1997-10-21	1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.

Legal Events

Date	Code	Title	Description
2007-01-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application